Brief: Grifols Strengthens Evidence For AMBAR In Alzheimer's With RWE Data

Grifols

21/09/2026 08:59

Sept 21 (Reuters) - Grifols, S.A. GRLS.MC:
STRENGTHENS EVIDENCE FOR AMBAR PROGRAM WITH NEW RWE DATA
AMBAR STUDY HAS SHOWN 61% REDUCTION IN DISEASE PROGRESSION IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE COMPARED WITH UNTREATED PATIENTS
AMBAR PROTOCOL BEGINS IMPLEMENTATION AT HOSPITALS IN SPAIN
COMPANY IALSO IN DISCUSSIONS WITH OTHER HOSPITALS ACROSS SPAIN TO EXPLORE PROGRESSIVE ADOPTION OF PROTOCOL AT ADDITIONAL CENTERS
FINDINGS EXPAND EVIDENCE RE APPLICABILITY OF THERAPEUTIC PLASMA EXCHANGE WITH ALBUMIN REPLACEMENT UNDER ROUTINE CLINICAL PRACTICE CONDITIONS
Source text: [ID:]
Further company coverage: GRLS.MC

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))